What happened with BCYC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bicycle Therapeutics plc designs short synthetic peptides held in two loops, called Bicycle molecules, to bind specific biological targets. Its cancer-treatment candidates attach cell-killing drugs or radioactive isotopes to these molecules to deliver them to tumors. It is prioritizing nuzefatide pevedotin and next-generation Bicycle conjugates, including candidates that carry radioactive isotopes.
Pharmaceutical partners pay Bicycle for access to its technology and for research that identifies and optimizes molecules for their targets. Collaboration payments supply most of its revenue; it has no products approved for sale and earns no product-sales revenue. Under agreements with Bayer and Ionis, partners take over further development and commercialization after the agreed research work. Future milestone payments and sales royalties therefore depend on those partners advancing the medicines.
Bicycle also develops its own candidates and uses equity financing alongside collaboration payments to fund its work. Turning those candidates into products requires clinical evidence of safety and effectiveness and regulatory approval; development still requires additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Bicycle Therapeutics’ prospects hinge on clinical success and collaboration payments, including its remaining Bayer program, with Eckert & Ziegler and SpectronRx supporting its radiopharmaceutical supply strategy.
Corbus Pharmaceuticals’ CRB-701 competes with Bicycle Therapeutics’ BT8009 to treat Nectin-4-expressing cancers; both attach the cancer-killing drug MMAE to tumor-targeting molecules. CRB-701’s clinical results offer a direct comparison for BT8009, rather than a marketed-product sales signal.
Ionis Pharmaceuticals licenses Bicycle Therapeutics’ peptides to deliver RNA-targeted medicines into tissues, giving Bicycle potential milestone payments and royalties as licensed drugs advance. Watch ION826 (AZD4063), which entered Phase 1 in December 2025 for PLN-R14del dilated cardiomyopathy.
Pfizer’s marketed Padcev sets the efficacy and safety benchmark for Bicycle Therapeutics’ Nectin-4-targeting cancer drug conjugates. Pfizer sells medicines, while Bicycle must show how its candidates compare, particularly on Padcev’s serious skin reactions and peripheral neuropathy that can limit dosing.
Aktis Oncology’s AKY-1189 competes with Bicycle Therapeutics’ Nectin-4 therapies by delivering radioactive isotopes to cancer targets. Aktis also earns collaboration revenue from Eli Lilly for research through initial human imaging studies, a step relevant to Bicycle’s own use of imaging to assess targets before treatment development.
Context Therapeutics’ CT-202 competes with Bicycle Therapeutics’ BT7480 by seeking to direct T cells against Nectin-4-expressing solid tumors. Context has no product sales; watch CT-202’s move toward human testing after its March 2026 application to Australia’s Bellberry Human Research Ethics Committee.
Eli Lilly’s Nectin-4 cancer medicines compete with Bicycle Therapeutics’ BT8009 for a future treatment market. Lilly develops and sells human medicines; progress on LY4052031 and LY4101174 is the relevant news for judging the alternatives BT8009 may face.
Radiopharm Theranostics and Bicycle Therapeutics both attach radioactive isotopes to tumor-targeting molecules for cancer imaging and treatment, making clinical validation and reliable isotope supply relevant to both. Radiopharm has no approved products for sale, so its cancer imaging and treatment trial results—not product revenue—are the useful comparison.
Bicycle Therapeutics plc earningsThis company
Bicycle Therapeutics relies on collaboration payments, not product sales, for revenue; its report will show whether cutting development costs is easing cash use as that income recedes.
Read collaboration revenue alongside research and development costs and operating cash use. If revenue falls but costs and cash use also narrow, the pipeline reset and workforce reduction are easing the funding burden. If revenue falls while costs and cash use remain high, the cuts have not yet caught up and the burden remains. Collaboration revenue can shift with the timing of milestones and other payments, so a high or low quarter is not a product-sales signal.
Pfizer Inc. earningsPFE
Pfizer’s report can show how demand for marketed Padcev and treatment-limiting effects shape the benchmark Bicycle Therapeutics’ Nectin-4 candidates must face.
Watch Pfizer’s disclosures on Padcev use and dose-limiting effects such as serious skin reactions and peripheral neuropathy. Sustained demand with these effects still a constraint means Bicycle’s candidates face an established treatment and its efficacy and safety bar; weaker demand or a changed safety picture would change that comparison.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis’s report can show whether licensed program ION826 is advancing, which matters to Bicycle Therapeutics’ potential future milestone and royalty receipts.
Watch Ionis’s update on ION826’s clinical progress and any disclosed movement in the collaboration. Continued advancement leaves a path to potential future milestones or royalties; a pause or setback weakens that possibility. Bicycle completed the research plan, and Ionis is responsible for subsequent development.
Corbus Pharmaceuticals Holdings, Inc. earningsCRBP
Corbus’s clinical results will show how another Nectin-4-targeting drug conjugate carrying MMAE performs, providing a direct comparison for Bicycle Therapeutics’ BT8009.
Watch CRB-701’s clinical activity and safety alongside BT8009’s development. Antitumor activity with manageable side effects would point to a direct competitor with the same target and payload; weak activity or treatment-limiting toxicity would make that comparison less compelling.
